Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia   - Episode 16

Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

, , , ,

The panel explores laboratory parameters routinely monitored for CRS and ICANS, including monitoring frequency, and discusses prophylactic measures and safety management strategies employed to address these complications in CAR-T therapy.

EP. 1: Overview of CAR T-cell Therapies in R/R B-cell ALL
EP. 2: CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel
EP. 3: Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL
EP. 4: Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment
EP. 5: Overview of Available Treatment Options in R/R B-cell ALL
EP. 6: Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives
EP. 7: Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
EP. 8: Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
EP. 9: Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy
EP. 10: Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment
EP. 11: Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting
EP. 12: Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL
EP. 13: Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy
EP. 14: Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL
EP. 15: Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy
Now Viewing
EP. 16: Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy
EP. 17: Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL
EP. 18: Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy
EP. 19: Role of Multidisciplinary Team & Logistics of CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting
EP. 20: Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Video content above is prompted by the following:

  • What labs do you routinely monitor for CRS and ICANs – and how frequently?
  • What type of prophylaxis and/or safety management are you applying to address CRS and ICANs?
  • Does your institution have a standard operating procedure or guideline?
    • What percentage of your patients have required either steroids, tocilizumab, and/or anakinra for CAR-related toxicities?
  • What are some other pertinent acute and long-term toxicities of CAR T-cell therapy to monitor for?
  • Do you utilize antimicrobial prophylaxis, growth factor agents and IV immunoglobulin in your practice?
  • When weighing treatment options, how heavily is CAR-T AE profile considered?
    • Does the safety profile of obe-cel change your perspective of using CAR-T? If so, how may it potentially affect your decision making?